YaoGeJu

Company directoryChina company filings

Guangzhou Ke Rui Te Pharma Co., Ltd. romanized

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference bf8c5059e3

Complete CDE snapshot
2026/11/13 06:42
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.

Drug filings

7 acceptance records as first applicant, grouped into 4 source drug names. Source data as of 2026/11/13 06:42.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Dasatinib Tablets 2 records · Latest accepted 2026/01/14

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2600178Generic2026/01/14Guangzhou Ke Rui Te Pharma Co., Ltd. romanizedCDE ↗
CYHS2600177Generic2026/01/14Guangzhou Ke Rui Te Pharma Co., Ltd. romanizedCDE ↗
Palbociclib Capsules 3 records · Latest accepted 2025/09/20

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2503483Generic2025/09/20Guangzhou Ke Rui Te Pharma Co., Ltd. romanizedCDE ↗
CYHS2503482Generic2025/09/20Guangzhou Ke Rui Te Pharma Co., Ltd. romanizedCDE ↗
CYHS2503481Generic2025/09/20Guangzhou Ke Rui Te Pharma Co., Ltd. romanizedCDE ↗
Ibrutinib Capsules 1 records · Latest accepted 2024/12/31

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2404637Generic2024/12/31Guangzhou Ke Rui Te Pharma Co., Ltd. romanizedCDE ↗
Axitinib Tablets 1 records · Latest accepted 2024/09/20

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2403127Generic2024/09/20Guangzhou Ke Rui Te Pharma Co., Ltd. romanizedCDE ↗

Changes in the last 90 days

0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

0 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Catalogue holder records

7 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Axitinib TabletsGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedGuangzhou Ke Rui Te Pharma Co., Ltd. romanized国药准字H202639892026/04/14Generic approved under the new chemical-drug registration classificationCDE ↗
Sunitinib Hard CapsulesGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedGuangzhou Ke Rui Te Pharma Co., Ltd. romanized国药准字H202547552025/06/30Generic approved under the new chemical-drug registration classificationCDE ↗
Imatinib Mesylate TabletsGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedGuangzhou Ke Rui Te Pharma Co., Ltd. romanized国药准字H202535132025/03/04Generic approved under the new chemical-drug registration classificationCDE ↗
Erlotinib Hydrochloride TabletsGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedGuangzhou Ke Rui Te Pharma Co., Ltd. romanized国药准字H202497922024/12/25Generic approved under the new chemical-drug registration classificationCDE ↗
Erlotinib Hydrochloride TabletsGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedGuangzhou Ke Rui Te Pharma Co., Ltd. romanized国药准字H202497932024/12/25Generic approved under the new chemical-drug registration classificationCDE ↗
Lenalidomide CapsulesGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedGuangzhou Ke Rui Te Pharma Co., Ltd. romanized国药准字H202493772024/11/15Generic approved under the new chemical-drug registration classificationCDE ↗
Lenalidomide CapsulesGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedGuangzhou Ke Rui Te Pharma Co., Ltd. romanized国药准字H202493762024/11/15Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

11 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.

NameCompany / applicantRegistration numberStatusSource update dateView source
曲美替尼二甲基亚砜 · No verified English nameGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedY20250001042I2025/10/13CDE ↗
达沙替尼 · No verified English nameGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedY20250000726I2025/09/04CDE ↗
甲苯磺酸索拉非尼 · No verified English nameGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedY20250000496I2025/06/13CDE ↗
哌柏西利 · No verified English nameGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedY20250000276I2025/04/02CDE ↗
甲苯磺酸拉帕替尼 · No verified English nameGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedY20240001334I2024/12/05CDE ↗
伊布替尼 · No verified English nameGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedY20240000976I2024/11/27CDE ↗
阿昔替尼 · No verified English nameGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedY20240000536A2026/10/05CDE ↗
苹果酸舒尼替尼 · No verified English nameGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedY20230000858A2025/11/04CDE ↗
甲磺酸伊马替尼 · No verified English nameGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedY20230000285A2025/03/15CDE ↗
盐酸厄洛替尼 · No verified English nameGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedY20220001100A2025/01/10CDE ↗
来那度胺 · No verified English nameGuangzhou Ke Rui Te Pharma Co., Ltd. romanizedY20220000832A2024/12/27CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39
Full API register
Last successful update: 2026/11/13 06:41
NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.